What: $1 billion licensing deal
Scoop: In May, Takeda continued its expansion in the U.S. with a $1 billion move into the RNAi field. In an alliance with RNAi powerhouse Alnylam, Takeda gained RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas in the future. Alnylam landed $100 million in up-front cash and an additional $50 million in near-term technology transfer payments. Takeda can expand the partnership in the future to include additional fields, with a payment of $50 million to Alnylam for each additional field. Finally, Alnylam will receive $171 million in milestones, along with royalties, for each product developed as part of the deal.